Flare Therapeutics Reveals FX-909 Phase 1 Study Results
Big pharma seduced by transcription factors again. What has changed?
Phase 1B trial of PPARG inhibitor launches in urothelial carcinoma
Roche teams up with transcription factor trailblazer Flare in new $1.8B-plus cancer pact
One to Watch – Flare Therapeutics
Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow
Flare Launches with $82 Million to Advance Novel Drug Discovery Approach for Transcription Factors
Sarah McCabe
investorrelations@flaretx.com
Timothy Cockroft
media@flaretx.com
This links to an external website.